BioAge Labs, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge Labs serves customers worldwide.

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-07)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BioAge Labs (BIOA US)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-07)

Current Report (Form 8-K | Period ending 2024-09-25)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

424B4 | Prospectus

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)